Daily non-political popular news in brief.

Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema

Researchers at Sarasota Memorial Health Care System today announced the start of the EASE trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a significant new, minimally-invasive option for those suffering with advanced widespread emphysema. The study focuses on a procedure called airway bypass that involves creating pathways in the lung for trapped air to escape and in turn, relieve emphysema symptoms including shortness of breath.

Read more »

Keywords: researchers, sarasota, memorial, health, care, system, study, airway, bypass, treatment, emphysema, researcher

« Previous | Next »

Similar news on "Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema":

1. Researchers at Penn study new airway bypass treatment to help emphysema sufferers breathe easier
   04-04-2007 · EurekAlert!
   Researchers at the University of Pennsylvania School of Medicine are now studying an investigational treatment that may offer a significant new, minimally-invasive option for those suffering from advanced widespread emphysema.
   Similar news · Read more »
   
2. Researchers at Pulmonary Associates to study airway bypass procedure for severe emphysema
   02-11-2008 · EurekAlert!
   Researchers at Pulmonary Associates today announced the start of the EASE Trial, a multicenter clinical trial to explore Airway Bypass, an investigational treatment that may offer a new, minimally invasive option for those suffering with advanced widespread emphysema.
   Similar news · Read more »
   
3. Researchers begin randomized double-blind trial of airway bypass treatment for emphysema
   05-17-2007 · EurekAlert!
   Broncus Technologies Inc., today announced the start of its EASE (Exhale Airway Stents for Emphysema) Trial to explore an investigational procedure that may offer a new, minimally-invasive treatment option for millions of emphysema sufferers. The study focuses on a procedure called airway bypass that uses drug-eluting stents to reinforce new pathways in the lung for trapped air to escape. This in turn, may relieve severe emphysema symptoms such as shortness of breath.
   Similar news · Read more »
   
4. Researchers at Cedars-Sinai Medical Center to study airway bypass treatment for emphysema
   06-06-2007 · EurekAlert!
   Researchers at Cedars-Sinai Medical Center announced today the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a new, minimally-invasive option for those suffering with advanced widespread emphysema.
   Similar news · Read more »
   
5. Electronic Health Record-based programs triples osteoporosis screening rate, study finds
   12-07-2006 · EurekAlert!
   A team of Geisinger Health System researchers in central Pennsylvania recently discovered that use of the Electronic Health Record in care programs significantly increases the screening rate of women who are at risk for osteoporosis. The study found that redesigning care to incorporate the EHR also helps streamline the work of doctors.
   Similar news · Read more »
   
6. Researchers at Peoria Pulmonary Associates to study airway bypass procedure for emphysema
   01-28-2008 · EurekAlert!
   Researchers at Peoria Pulmonary Associates today announced the start of the EASE Trial, an international, multi-center clinical trial to explore an investigational procedure for advanced widespread emphysema/COPD. Conducted at Methodist Medical Center, the study focuses on a procedure called airway bypass. Airway bypass is a bronchoscopic procedure designed to reduce lung hyperinflation and shortness of breath (the clinical hallmarks of emphysema/COPD) by making new pathways for trapped air to exit the lungs.
   Similar news · Read more »
   
7. Cancer patients may benefit from reporting symptoms online in real time
   11-29-2007 · EurekAlert!
   A new study by researchers at Memorial Sloan-Kettering Cancer Center finds that even the sickest cancer patients are willing and able to "self-report" symptoms using the Internet, thus supplying key data in real time to their health-care providers.
   Similar news · Read more »
   
8. New York Methodist Hospital to study airway bypass treatment for emphysema
   02-04-2008 · EurekAlert!
   New York Methodist Hospital today announced the start of the EASE Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a significant new, minimally-invasive option for those suffering with advanced widespread emphysema. The study focuses on a procedure called airway bypass that involves creating pathways in the lung for trapped air to escape and in turn, relieve emphysema symptoms including shortness of breath.
   Similar news · Read more »
   
9. Firms covering large majority of nation's workers view health benefits as important recruitment tool
   11-14-2006 · EurekAlert!
   Despite intense health care cost pressures, firms covering more than 90 percent of the nation's workforce view health benefits as an important tool to attract and retain qualified workers, according to a national study by researchers at the Center for Studying Health System Change (HSC) and the Commonwealth Fund published in the November/December edition of Health Affairs.
   Similar news · Read more »
   
10. Advance in understanding of blood pressure gene could lead to new treatments
    02-04-2007 · EurekAlert!
    Research by scientists at UCL (University College London) has clearly demonstrated for the first time the structure and function of a gene crucial to the regulation of blood pressure. The discovery could be important in the search for new treatments for illnesses such as heart disease, the UK's biggest killer. In a paper published online today in Nature Medicine, the team, led by Professor Patrick Vallance and Dr James Leiper, UCL Department of Medicine, reveal the role of the human gene dimethylarginine dimethylaminohydrolase (DDAH), showing that loss of DDAH activity disrupts nitric oxide (NO) production. NO is critical in the regulation of blood pressure, nervous system functions and the immune system. The role of DDAH is to break down modified amino acids (Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA)) that are produced by the body and have been shown to inhibit NO synthase. These molecules accumulate in various disease states including diabetes, renal failure and pulmonary and systemic hypertension, and their concentration in plasma (the fluid component of blood) is strongly predicative of cardiovascular disease and death. In a healthy human body, the majority of ADMA is eliminated through active metabolism by DDAH. Scientists have hypothesised that if DDAH function is impaired, NO production is reduced, and that this could be an important feature of increased cardiovascular risk. To examine this pathway in more detail, the researchers deleted the DDAH gene in mice. These mice went on to develop hypertension, or high blood pressure. They also designed specific inhibitors (small molecules) which bind to the active site of human DDAH. These small molecule inhibitors also induced hypertension in mice, confirming the importance of DDAH in the regulation of blood pressure. Dr Leiper, UCL Medicine, said: “These genetic and chemical approaches to disrupt DDAH showed remarkably consistent results, and provide compelling evidence that loss of DDAH function increases the concentration of ADMA and thereby disrupts vascular NO signalling. “There has been considerable scientific interest in this pathway and the role of ADMA as a novel risk factor, but so far there's been little evidence to support the idea that it's a cause of disease, rather than just a marker. Genes and their pathways are crucial to our understanding of cardiovascular disease and a better understanding of DDAH-1 could lead to important new treatments. “It could help us to establish if genetic variation predisposes certain people to these diseases, or whether environmental factors exert some of their effects through modulation of DDAH activity. “Our research also shows that this pathway could be harnessed therapeutically to limit production of NO in certain situations where too much nitric oxide is a bad thing; for example, hypotension and septic shock. These are some of the biggest problems in intensive care medicine and there is a huge unmet need for drug treatments.” The study, which was carried out at UCL's Rayne Institute, was funded by grants from the British Heart Foundation, the Wellcome Trust and the Medical Research Council. Professor Jeremy Pearson, Associate Medical Director of the British Heart Foundation, said: "The unexpected finding in the 1980s that a simple gas, nitric oxide (NO), is made by cells in the blood vessel wall and is a powerful control of blood vessel relaxation led to the award of the Nobel Prize in 1998 to its discoverers. "More recently, there has been increasing evidence that impairment of NO production is likely to be an important factor in the development of heart and circulatory disease, but the mechanisms responsible are not fully understood. "This study suggests for the first time that the loss of the activity of the enzyme DDAH-1 leads to reduced NO production and may cause heart and circulatory disease. These findings are likely to be important in the search for new ways to optimise the health of our blood vessels." ### Notes for Editors 1. For more information, please contact Ruth Metcalfe in the UCL Media Relations Office on tel: +44 (0)20 7679 9739, mobile: +44 (0)7990 675 947, out of hours: +44 (0)7917 271 364, e-mail: r.metcalfe@ucl.ac.uk2. 'Disruption of methylarginine metabolism impairs vascular homeostasis' is published in the February issue of the journal Nature Medicine. Advance online publication is embargoed to 18.00 GMT (13.00 US Eastern) Sunday 4 February 2007. Journalists can obtain copies of the paper by contacting the UCL Media Relations Office.3. The study was funded by the British Heart Foundation, the Wellcome Trust and the Medical Research Council. About UCL Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the government's most recent Research Assessment Exercise, 59 UCL departments achieved top ratings of 5* and 5, indicating research quality of international excellence. UCL is the fourth-ranked UK university in the 2006 league table of the top 500 world universities produced by the Shanghai Jiao Tong University. UCL alumni include Mahatma Gandhi (Laws 1889, Indian political and spiritual leader); Jonathan Dimbleby (Philosophy 1969, writer and television presenter); Junichiro Koizumi (Economics 1969, Prime Minister of Japan); Lord Woolf (Laws 1954, Lord Chief Justice of England & Wales); Alexander Graham Bell (Phonetics 1860s, inventor of the telephone), and members of the band Coldplay.
    Similar news · Read more »